Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon
Journal of Obesity · 2025-01 · 2025 (1)
DOI: 10.1155/jobe/9919810 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Obesity, online erschienen am 24.11.2025. Verfasst von Riad Mohammed Abdelrahman und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Graduate Studies and Scientific Research, National Ribat University, Khartoum, Sudan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Obesity has emerged as a pressing global health challenge, and therapies based on glucagon‐like Peptide 1 receptor agonists (GLP‐1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA‐approved for obesity treatment, while other agents are used off‐label. These drugs not only provide unprecedented efficacy and acceptable safety in weight reduction and glycemic control for patients with obesity and Type 2 diabetes but also hold promise in broader indications, including neurodegenerative disorders, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular conditions.
Methods
This narrative review examined the therapeutic applications of GLP‐1RAs for obesity, emphasizing their efficacy, safety profile, challenges with patient adherence, and limitations. The review also explored emerging innovations such as ultralong‐acting formulations, combination therapies, and the integration of digital health and artificial intelligence in advancing antiobesity drug development.
Results
GLP‐1RAs represent a paradigm shift in the treatment of obesity and metabolic diseases, with rapidly expanding indications and global uptake. Recent evidence highlights improvements in tolerability, global accessibility, and the potential of novel technologies to optimize patient outcomes. By 2025, GLP‐1RAs are anticipated to receive FDA approval for new indications, such as chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction–associated steatohepatitis. Novel agents including CagriSema and higher dose oral semaglutide are advancing through clinical trials, while pivotal trial results for orforglipron, mazdutide, retatrutide, and survodutide are anticipated to further expand the therapeutic landscape. At the same time, the arrival of generic liraglutide and evolving insurance coverage are reshaping access and affordability.
Conclusion
The convergence of pharmacological innovation, digital health strategies, and equitable care initiatives is expected to revolutionize obesity therapeutics in the coming decade. Priorities for future research include sustaining long‐term weight loss, establishing disease‐modifying potential in nonmetabolic disorders, and addressing health equity concerns to ensure broader global benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Graduate Studies and Scientific Research, National Ribat University, Khartoum, Sudan.
- Faculty of Pharmacy, National Ribat University, Khartoum, Sudan.
- Pharmacy Program, School of Medical & Health Sciences, Libyan International University, Benghazi, Libya.
- School of Medicine & Biomedical Research Institute, Darfur University College, Nyala, Sudan.
- Department of Pharmacy Practice, Faculty of Pharmacy, International University of Africa, Khartoum, Sudan.
- Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan.
ORCID-Profile: Riad Mohammed Abdelrahman, Taha Hussein Musa, Ismail Adam Arbab, Mohsen Hussein Suliman, Eltieb Omer Ahmed, Asma Noureldaim Mohamed, Hassan Hussein Musa, Mohammed Jalal, Sahar Ibrahim Gasmallah
Zitieren
APA
Abdelrahman, R. M., Musa, T. H., Arbab, I. A., Suliman, M. H., Ahmed, E. O., Mohamed, A. N., Musa, H. H., Jalal, M., & Gasmallah, S. I. (2025). Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. Journal of Obesity, 2025(1). https://doi.org/10.1155/jobe/9919810
Vancouver
Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN, et al. Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon. Journal of Obesity. 2025;2025(1). doi:10.1155/jobe/9919810
BibTeX
@article{Abdelrahman2025,
author = {Abdelrahman, Riad Mohammed and Musa, Taha Hussein and Arbab, Ismail Adam and Suliman, Mohsen Hussein and Ahmed, Eltieb Omer and Mohamed, Asma Noureldaim and Musa, Hassan Hussein and Jalal, Mohammed and Gasmallah, Sahar Ibrahim},
title = {Harnessing GLP‐1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon},
journal = {Journal of Obesity},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/jobe/9919810}
}
EUVIMED